Radioembolization (Y90) has been proven safe and effective in the treatment of patients
with hepatocellular carcinoma.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Clinical RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015.JAMA Oncol. 2017; 3: 1683-1691
- Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study.Gastroenterology. 2004; 127: 1372-1380
- Risk factors for hepatocellular carcinoma among patients with chronic liver disease.N Engl J Med. 1993; 328: 1797-1801
- Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.Gastroenterology. 2010; 138: 1747-1754
- Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women.Am J Epidemiol. 2002; 155: 323-331
- The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.Hepatology. 2010; 51: 1972-1978
- EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol. 2012; 56: 908-943
- Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.Ann Surg. 2015; 261: 947-955
- Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China.JAMA Surg. 2019; 154: 209-217
- Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med. 1996; 334: 693-699
- Management of hepatocellular carcinoma: an update.Hepatology. 2011; 53: 1020-1022
- Locoregional therapy of hepatocellular carcinoma.Clin Liver Dis. 2015; 19: 401-420
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.Lancet. 2002; 359: 1734-1739
- Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients.Cardiovasc Intervent Radiol. 2008; 31: 269-280
- Yttrium-90 microspheres: radiation therapy for unresectable liver cancer.J Vasc Interv Radiol. 2002; 13: S223-S229
- Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes.Gastroenterology. 2010; 138: 52-64
- Chemoembolization and radioembolization for hepatocellular carcinoma.Clin Gastroenterol Hepatol. 2013; 11 ([quiz: e43–4]): 604-611
- Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.J Nucl Med. 2015; 56: 339-346
- Same-day 90Y radioembolization: implementing a new treatment paradigm.Eur J Nucl Med Mol Imaging. 2016; 43: 2353-2359
- Side effects of yttrium-90 radioembolization.Front Oncol. 2014; 4: 198
- Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations.J Vasc Interv Radiol. 2006; 17: 1251-1278
- Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study.Hepatology. 2013; 57: 1826-1837
- Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST.Semin Liver Dis. 2014; 34: 444-455
- Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma.Gastroenterology. 2016; 150: 835-853
- Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma.Radiology. 2018; 287: 1050-1058
- Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations.J Nucl Med. 2006; 47: 1209-1211
- Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma.Eur J Nucl Med Mol Imaging. 2018; 45: 392-401
- Dosimetry of Y-90 Microspheres Utilizing Tc-99m SPECT and Y-90 PET.Semin Nucl Med. 2019; 49: 211-217
- Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization.J Vasc Interv Radiol. 2009; 20: 606-613
- Technical aspects and practical approach toward same-day Y90 radioembolization in the management of hepatocellular carcinoma.Tech Vasc Interv Radiol. 2019; 22: 93-99
- Same-Day Yttrium-90 radioembolization: feasibility with resin microspheres.J Vasc Interv Radiol. 2019; 30: 314-319
- Beta on demand: the adoption of same-day yttrium-90 radioembolization.J Vasc Interv Radiol. 2019; 30: 320-322
- Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization.Int J Radiat Oncol Biol Phys. 2011; 79: 163-171
- Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy.Hepatology. 2014; 60: 192-201
- Radiation Segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study.Radiology. 2017; 283: 895-905
- Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study.J Vasc Interv Radiol. 2017; 28: 777-785.e1
- Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization.Ann Surg Oncol. 2009; 16: 1587-1596
- Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.J Hepatol. 2013; 59: 1029-1036
- Volumetric changes after 90Y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?.Ann Surg Oncol. 2013; 20: 2518-2525
- Neoadjuvant radiation lobectomy as an alternative to portal vein embolization in hepatocellular carcinoma.Semin Nucl Med. 2019; 49: 197-203
- (90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes.J Surg Oncol. 2016; 114: 99-105
- Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma.J Vasc Interv Radiol. 2018; 29: 1502-1510.e1
- Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma.Eur J Surg Oncol. 2012; 38: 594-601
- Modified radiation lobectomy: an evolving paradigm to convert patients to liver resection candidacy.Semin Interv Radiol. 2019; 36: 343-348
- Three-dimensional C-arm cone-beam CT: applications in the interventional suite.J Vasc Interv Radiol. 2009; 20: S523-S537
- Research reporting standards for radioembolization of hepatic malignancies.J Vasc Interv Radiol. 2011; 22: 265-278
- Institutional decision to adopt Y90 as primary treatment for HCC informed by a 1,000-patient 15-year experience.Hepatology. 2018; 68: 1429-1440
- Radiologic findings following Y90 radioembolization for primary liver malignancies.Abdom Imaging. 2009; 34: 566-581
- Hepatic imaging following intra-arterial embolotherapy.Abdom Radiol (NY). 2016; 41: 600-616
- Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma.J Vasc Interv Radiol. 2015; 26: 69-73
- Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization.Cardiovasc Intervent Radiol. 2006; 29: 522-529
- Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer.J Med Imaging Radiat Oncol. 2011; 55: 111-118
- Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma.Abdom Radiol (NY). 2018; 43: 1723-1738
- Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.J Hepatol. 2011; 54: 695-704
- Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses.Hepatology. 2018; 67: 873-883
- Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma.J Vasc Interv Radiol. 2016; 27: 795-802
- Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.Hepatology. 2011; 54: 868-878
- Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma.Gastroenterology. 2016; 151: 1155-1163.e2
- 03:54 PM Abstract No. 331 Radioembolization for hepatocellular carcinoma patients within Milan criteria: bridging and beyond.J Vasc Interv Radiol. 2019; 30: S146
- A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.Am J Transplant. 2009; 9: 1920-1928
- Treatment of intermediate-stage hepatocellular carcinoma.Nat Rev Clin Oncol. 2014; 11: 525-535
- Cone Beam Computed Tomography (CBCT) in the field of interventional oncology of the liver.Cardiovasc Intervent Radiol. 2016; 39: 8-20
- Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.J Vasc Interv Radiol. 2014; 25: 1067-1073
- Superselective Yttrium-90 radioembolization for hepatocellular carcinoma in high-risk cases: another tool in the toolbox.J Vasc Interv Radiol. 2014; 25: 1073-1074
- Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression.J Hepatol. 2013; 58: 73-80
- Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.J Vasc Interv Radiol. 2007; 18: 1375-1382
- Survival analysis of advanced HCC treated with radioembolization: comparing impact of clinical performance status versus vascular invasion/metastases.Cardiovasc Intervent Radiol. 2018; 41: 260-269
- AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology. 2018; 67: 358-380
- Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.Hepatology. 2008; 47: 71-81
- Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.Eur J Nucl Med Mol Imaging. 2013; 40: 1057-1068
- Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.J Hepatol. 2018; 68: 724-732
- Sorafenib in advanced hepatocellular carcinoma.N Engl J Med. 2008; 359: 378-390
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 389: 56-66
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet. 2018; 391: 1163-1173
- Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.J Hepatol. 2019; 71: 543-552
- Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.Lancet Oncol. 2017; 18: 1624-1636
- SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma.J Clin Oncol. 2018; 36: 1913-1921
- (90)Y Radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort.J Nucl Med. 2018; 59: 1042-1048
- Radioembolization in advanced hepatocellular carcinoma.J Clin Oncol. 2018; 36: 1898-1901
- The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The Soramic trial palliative cohort.J Hepatol. 2018; 68: S102
- Objective Response by mRECIST is an independent prognostic factor for overall survival in hepatocellular carcinoma treated with Sorafenib in the SILIUS trial.Liver Cancer. 2019; 8: 505-519
- Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.J Hepatol. 2017; 66: 1166-1172
- Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.J Vasc Interv Radiol. 2020; 31: 25-34
- Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.JMIR Res Protoc. 2018; 7 (e11234-e)
- A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.J Clin Oncol. 2016; 34: TPS4147
- 4: 03 PM Abstract No. 268 Role of Y90 radioembolization in BCLC D patients.J Vasc Interv Radiol. 2018; 29: S115-S116
Article info
Publication history
Published online: May 31, 2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
